- Home
- REPX vs FTH Comparison
REPX vs FTH Comparison
Compare REPX & FTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
HOLD
N/A
Current Price
$27.34
Company Overview
Basic Information| Metric | REPX | FTH |
|---|---|---|
| Founded | 2016 | N/A |
| Country | United States | United States |
| Employees | N/A | 29 |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 764.6M | 860.0M |
| IPO Year | 2003 | 2021 |
Fundamental Metrics
Financial Performance| Metric | REPX | FTH |
|---|---|---|
| Price | $34.13 | $27.34 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 4 | 0 |
| Target Price | ★ $45.00 | N/A |
| AVG Volume (30 Days) | 185.3K | ★ 264.5K |
| Earning Date | 05-06-2026 | N/A |
| Dividend Yield | ★ 4.41% | N/A |
| EPS Growth | ★ 78.17 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $3,038,000.00 | N/A |
| Revenue This Year | $33.41 | N/A |
| Revenue Next Year | $13.46 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $24.08 | $17.50 |
| 52 Week High | $41.53 | $37.90 |
Technical Indicators
Market Signals| Indicator | REPX | FTH |
|---|---|---|
| Relative Strength Index (RSI) | 49.16 | 48.87 |
| Support Level | $32.93 | $22.47 |
| Resistance Level | $34.47 | $31.61 |
| Average True Range (ATR) | 1.04 | 3.25 |
| MACD | -0.07 | -0.40 |
| Stochastic Oscillator | 33.19 | 28.14 |
Price Performance
Historical Comparison REPX
FTH
About REPX Riley Exploration Permian Inc.
Riley Exploration Permian Inc is engaged in the business of exploration for and production of oil and natural gas. The company operations include: The Permian Basin is an oil and natural gas producing area located in West Texas.
About FTH Faeth Therapeutics Inc. Common Stock
Faeth Therapeutics Inc is a clinical-stage biotechnology company focused on improving outcomes for cancer patients through multi-node inhibition of critical oncogenic pathways. The company's principal program is PIKTOR, an investigational all-oral combination of serabelisib and sapanisertib in development for endometrial and breast cancer.